BCL2 and acute myeloid leukemia: Indeed, hematopoietic stem/progenitor cells from patients with ASXL1-mutated AML have a higher expression of BCL2 [94], and relapsed–refractory ASXL1-mutated AML treated with HMA and VEN had improved CR/CRi rates in a retrospective study [92].